Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the company’s stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $40.26, for a total transaction of $805,200.00. Following the completion of the sale, the executive vice president directly owned 20,000 shares in the company, valued at approximately $805,200. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Marshall Urist also recently made the following trade(s):

• On Friday, January 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.52, for a total transaction of $790,400.00.
• On Friday, January 9th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $40.78, for a total transaction of $815,600.00.
• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total value of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total transaction of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Stock Up 0.3%

NASDAQ:RPRX traded up $0.11 during trading hours on Monday, reaching $40.51. The company had a trading volume of 5,086,791 shares, compared to its average volume of 3,851,069. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89. The business’s 50-day simple moving average is $39.35 and its two-hundred day simple moving average is $37.58. The firm has a market cap of $23.38 billion, a price-to-earnings ratio of 30.69, a P/E/G ratio of 1.54 and a beta of 0.43. Royalty Pharma PLC has a twelve month low of $29.66 and a twelve month high of $41.70.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.06. The business had revenue of $609.29 million for the quarter, compared to analyst estimates of $765.01 million. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%. On average, equities analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be paid a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 2.3%. This is a positive change from Royalty Pharma’s previous quarterly dividend of $0.22. The ex-dividend date of this dividend is Friday, February 20th. Royalty Pharma’s payout ratio is 66.67%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on RPRX. Wall Street Zen upgraded shares of Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. Leerink Partners set a $45.00 price objective on Royalty Pharma in a report on Thursday, December 11th. Weiss Ratings restated a “hold (c+)” rating on shares of Royalty Pharma in a report on Thursday. The Goldman Sachs Group initiated coverage on Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target for the company. Finally, TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research note on Thursday, December 11th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

Institutional Trading of Royalty Pharma

A number of large investors have recently added to or reduced their stakes in RPRX. Capital International Investors boosted its holdings in shares of Royalty Pharma by 24.4% in the third quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock worth $960,064,000 after acquiring an additional 5,332,074 shares during the period. Norges Bank bought a new stake in shares of Royalty Pharma during the 2nd quarter valued at $181,388,000. Dorsey Asset Management LLC purchased a new stake in Royalty Pharma during the 3rd quarter worth about $82,924,000. Qube Research & Technologies Ltd boosted its stake in Royalty Pharma by 737.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 2,481,771 shares of the biopharmaceutical company’s stock worth $87,557,000 after purchasing an additional 2,185,366 shares during the period. Finally, Millennium Management LLC grew its holdings in Royalty Pharma by 379.2% during the 3rd quarter. Millennium Management LLC now owns 2,235,133 shares of the biopharmaceutical company’s stock valued at $78,855,000 after buying an additional 1,768,702 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.